GRAIL, Inc.

Our Company is a commercial-stage healthcare company focused on early cancer detection at population scale. The company's mission is to detect cancer early, when it can be cured. Its multi-cancer early detection test, "Galleri," screens for many types of cancer from a simple blood draw. Galleri accurately predicts the specific organ or tissue type where the cancer signal originated (the "Cancer Signal of Origin," or "CSO"), with high positive predictive values ("PPV") and low false positive rates. Galleri has detected aggressive cancers in early stages, including endometrial, esophageal, gastrointestinal, head and neck, liver, pancreatic, and rectal cancers. The company has conducted a clinical program with data from over 385,000 participants. Over 800,000 tests have been processed across this clinical program and from commercial experience, including through partnerships with healthcare systems, employers, digital health platforms, payors, and life insurance providers. The company announced results from two large clinical trials, PATHFINDER 2 and NHS-Galleri Trial, and included certain results in its pre-market approval application ("PMA") to the Food and Drug Administration ("FDA"), with the last module submitted in January 2026. Performance and safety data from the first approximately 25,000 participants of the approximately 35,000 participant PATHFINDER 2 study were presented in October 2025. These "PATHFINDER 2 Initial Results" showed that adding Galleri to recommended screenings (breast, cervical, colorectal, and lung) led to a cancer detection rate more than a seven-fold increase in cancers found within a year, and an approximately three-fold increase when prostate screening was included.